Exploring the Intersection: A Comprehensive Review of HIV and Breast Cancer

Anna Dardzińska^*
*Correspondence: Anna Dardzińska, Department of Rheumatology, Medical University of Gdańsk, Dębinki 7, 80-211 Gdańsk, Poland, Email:

Introduction

The intersection of HIV and breast cancer presents a complex and critical area of study, revealing significant implications for the management and outcomes of affected individuals. HIV (Human Immunodeficiency Virus) is a chronic virus that impairs the immune system, leaving individuals susceptible to a range of opportunistic infections and malignancies. Breast cancer, a malignancy originating in breast tissue, is the most common cancer among women worldwide and represents a major public health challenge. The convergence of these two serious health conditions raises important questions about their interaction, management strategies, and the impact on patient outcomes [1].

Historically, the research on HIV and cancer has predominantly focused on Kaposi's sarcoma, non-Hodgkin's lymphoma, and invasive cervical cancer, which are more strongly associated with HIV infection. However, emerging evidence suggests that breast cancer, typically considered less directly linked to HIV, may also be influenced by the presence of HIV. This growing recognition highlights the need for a more nuanced understanding of how HIV affects breast cancer incidence, progression, and treatment responses. In this review, we will delve into the current knowledge regarding the intersection of HIV and breast cancer, examining the epidemiology, pathophysiological mechanisms, diagnostic challenges, and treatment considerations. By exploring these aspects, we aim to provide a comprehensive overview of how HIV may influence breast cancer outcomes and to identify areas where further research is needed.

Description

The epidemiological relationship between HIV and breast cancer is complex. Women living with HIV are generally at increased risk for various malignancies due to their immune compromised state. Breast cancer, being the most prevalent cancer among women, also affects those with HIV, though the incidence rates and outcomes can differ from the general population. Studies indicate that women with HIV may have a slightly lower or similar incidence of breast cancer compared to the general population. However, this could be influenced by several factors, including lower life expectancy due to HIV-related complications and variations in screening practices. The incidence of breast cancer in HIV-positive women has been reported to be lower in some studies, possibly due to competing mortality from AIDS-related illnesses and underrepresentation of HIV-positive women in breast cancer screening programs.

The interaction between HIV and breast cancer involves several intricate mechanisms. HIV affects the immune system, leading to chronic immune activation and inflammation, which can influence cancer development and progression. The immunosuppressive effects of HIV can lead to a reduced ability to detect and destroy malignant cells, potentially allowing for the development and progression of breast cancer. Moreover, HIV-induced inflammation and immune dysregulation may impact breast cancer progression. Chronic inflammation is known to contribute to carcinogenesis, and HIV-related immune dysfunction might exacerbate this process [2]. The role of Antiretroviral Therapy (ART) in this context is also significant, as ART can influence immune function and may interact with cancer therapies.

The diagnosis of breast cancer in HIV-positive individuals presents unique challenges. HIV-positive patients may experience delays in cancer diagnosis due to overlapping symptoms of HIV and cancer, as well as potential stigmatization and disparities in healthcare access. Additionally, the presence of HIV can complicate the interpretation of diagnostic tests and imaging studies. Screening guidelines for breast cancer in HIV-positive women are not as well established as those for the general population. Regular mammography is recommended for women over 40, but the timing and frequency of screenings in HIV-positive women may need to be tailored based on individual health conditions and risk factors [3].

The treatment of breast cancer in HIV-positive women requires a multidisciplinary approach, considering both the cancer and HIV management. ART is crucial for controlling HIV and improving overall health, but its interactions with cancer therapies need careful management. Certain ART drugs may interact with chemotherapeutic agents, potentially affecting their efficacy and toxicity profiles. Managing side effects is another critical aspect, as both HIV and cancer treatments can have overlapping toxicities. For example, immunosuppressive effects from both HIV and cancer therapies might increase the risk of infections, complicating the treatment course [4,5]. Furthermore, HIV-positive women may have different responses to breast cancer treatments compared to their HIV-negative counterparts. There is ongoing research to understand how HIV status affects the efficacy and side effects of various breast cancer treatments, including surgery, chemotherapy, radiation, and targeted therapies.

Conclusion

Navigating the nexus of HIV and breast cancer involves understanding a range of epidemiological, pathophysiological, diagnostic, and treatment-related factors. Women living with HIV face unique challenges when dealing with breast cancer, including increased complexity in diagnosis and treatment, as well as potential impacts on outcomes. While the incidence of breast cancer in HIV-positive women may not be significantly higher than in the general population, the presence of HIV can influence cancer progression and complicate treatment. The interactions between HIV and breast cancer therapies require careful consideration to optimize patient outcomes and manage potential drug interactions and side effects.

Future research is essential to further elucidate the relationship between HIV and breast cancer, particularly focusing on improving screening guidelines, understanding the impact of ART on cancer progression, and refining treatment approaches. By addressing these areas, healthcare providers can better support HIV-positive women with breast cancer, ultimately leading to improved management strategies and outcomes. In conclusion, the intersection of HIV and breast cancer underscores the need for a nuanced and integrated approach to patient care. Enhanced awareness, research, and tailored treatment strategies are crucial to addressing the unique needs of this patient population and improving their overall health and quality of life.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Yarchoan, Robert and Thomas S. Uldrick. "HIV-associated cancers and related diseases." NEJM 378 (2018): 1029-1041.

Google Scholar, Crossref, Indexed at

2. Park, Boyoung, Kyoung Hwan Ahn, Yunsu Choi and Jung Ho Kim, et al "Cancer incidence among adults with HIV in a population-based cohort in Korea." JAMA Netw Open 5 (2022): e2224897-e2224897.

Google Scholar, Crossref, Indexed at

3. Chiao, Elizabeth Y., Anna Coghill, Darya Kizub and Valeria Fink, et al. "The effect of non-AIDS-defining cancers on people living with HIV." Lancet Oncol 22 (2021): e240-e253.

Google Scholar, Crossref, Indexed at

4. Yuan, Tanwei, Yuqing Hu, Xinyi Zhou and Luoyao Yang, et al. "Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis." EClinicalMedicine 52 (2022).

Google Scholar, Crossref, Indexed at

5. Sun, Yi-Sheng, Zhao Zhao, Zhang-Nv Yang and Fang Xu, et al. "Risk factors and preventions of breast cancer." Int J Biol Sci (2017): 1387.

Google Scholar, Crossref, Indexed at